Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes

NeuroImmunoModulation

Volumn 9, Issue 4, 2001, Pages 203-208

  Nadlinger, Karl ^a   Birkmayer, Jörg ^a   Gebauer, Frank ^b   Kunze, Rudolf ^b  

^a Labor Birkmayer und Medinfo GmbH   (Austria)

^b Affina Immuntechnik GmbH   (Germany)

Author keywords

Inflammation; Interleukin 6; NADH; Neurodegenerative disorders; Reduced nicotinamide adenine dinucleotide

Indexed keywords

INTERLEUKIN 6; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; INCUBATION TIME; LEUKOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; INTERLEUKINS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; NAD; STIMULATION, CHEMICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035719636     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049027     Document Type: Article

References (39)

1. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson's disease
2. Stimulation of dopamine biosynthesis in cultured PC12 phaeochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH)
3. Nicotinamide adenine dinucleotide (NADH) as medication for Parkinson's disease. Experience with 415 patients
4. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent
5. Coenzyme nicotinamide adenine dinucleotide. New therapeutic approach for improving dementia of the Alzheimer type
6. Amine precursors, amine and false neurotransmitters in depressed patients
7. Excretion of 3-methoxy-4-hydroxymandelic acid (VMA) in depressed patients with antidepressant drugs
8. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients
9. Focal inflammation in the brain. Role in Alzheimer disease
10. 'Inflammatory cytokines': Neuromodulators in normal brain?
11. Inflammation and Alzheimer's disease
12. Changing responsiveness of developing midbrain dopaminergic neurons for extra-cellular growth factors
13. Ionic and signal transduction alterations in Alzheimer's disease: Relevance of studies on peripheral cells
14. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals
15. Decreased phagocytic function in patients with Parkinson's disease
16. Interleukin-6 and its receptor: Ten years later
17. Interleukin-6 signal transduction and lymphocyte function
18. Activated phosphorylation of cyclic AMP responsive element binding protein is associated with preservation of striatal neurons after focal cerebral ischemia in the rat
19. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two week old rats in cultures
20. Hypoxia/reoxygenation-mediated induction of astrocyte interleukin-6: A paracrine mechanism potentially enhancing neuronal survival
21. Possible involvement of catalase in the protective effect of interleukin-6 against 6-hydroxydopamine toxicity in PC12 cells
22. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitoxicity in the brain
23. Brain endothelial cell production of a neuroprotective cytokine, interleukin-6, in response to noxious stimuli
24. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat
25. Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
26. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
27. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease
28. Decreased interleukin-6 levels in the cerebrospinal fluid of patients with Alzheimer type dementia
29. Neural activities of IL-6 type cytokines often depend on soluble cytokine receptors
30. Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis
31. Passage of cytokines across the blood-brain barrier
32. Differential transport of rat and human interleukin 1α across the blood-brain barrier and blood-testis barrier in rats
33. Penetration of neutrophins and cytokines across the blood-brain/blood-spinal cord barrier
34. Basic mechanisms of brain inflammation
35. Intrathecal and serum interleukin-6 and the acute phase response in patients with severe traumatic brain injuries
36. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats
37. Interleukin-6 - A molecule with both beneficial and destructive potential
38. Mechanisms and consequences of nerve cell death in Parkinson's disease
39. The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease